After Obesity, What Are Biopharma’s Big Growth Markets?

The five therapy areas forecast to achieve the highest growth between 2024 and 2030 include a mixture of the more obvious (MASH) and less high profile (glioma). In some cases, which companies will seize market share remains up for grabs.

(Shutterstock)

After the explosive increase in the obesity market size led by GLP-1 agonist therapies in the last few years, the natural question is: what will biopharma’s next big growth markets be?

Scrip has interrogated Evaluate’s databases to provide a forecast of which segments will be the fastest growing for the 2024 to 2030 period, drawing on a range of sources to provide the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Alimentary/Metabolic